Un caso de cáncer ovárico de célula pequeña hipercalcémico / No disponible

El carcinoma ovárico de célula pequeña hipercalcémicoes un tumor raro y agresivo con mayor incidenciaen mujeres jóvenes.La hipercalcemia es una de sus características clínicas.El tratamiento multidisciplinar parece incrementarla supervivencia en un número pequeño de casos.Presentamos el caso de una mujer diagnosticadade este tipo de tumor, su evolución clínica y el tratamientoque recibió

The hypercalcemic ovarian small cell carcinomais a very rare aggressive tumor affecting young women.Hypercalcemia is among its clinical features.Prognosis is poor despite aggressive treatment,but combined treatment seems to increase survivalin a small subset of patients.We report a case of a woman diagnosed of hypercalcemicovary small cell cancer, her clinical evolution and the treatment she received (AU)

Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.

A study of 32 patients receiving cyclophosphamide (CY) and verapamil (VER) in addition to the drug combination vincristine, adriamycin and methyl prednisolone (VAMP) was made in which the clinical response and growth of clonogenic myeloma cells (MY-CFUc) from bone marrow aspirates were compared. At presentation, MY-CFUc were grown from 72 per cent (23/32) of the patients. After treatment with CY-VAMP or VERCY-VAMP, MY-CFUc were grown from 25 per cent (8/32) of patients of whom only 50 per cent responded clinically. The overall clinical response rate for patients receiving CY-VAMP and VERCY-VAMP was 64 per cent (9/14) and 72 per cent (13/18) respectively of whom 14 per cent in each group achieved complete remission. There was no concomitant increase in normal tissue toxicity as measured by granulocyte-macrophage colony (GM-CFUc) formation. Comparison of these data with our previous study of patients receiving VAMP alone, suggests that the addition of CY to the regimen may increase the tumour cell kill. Further clinical studies will determine whether there is a significant increase in the complete remission rate.